June 2022 Federal Circuit Newsletter (Japanese) June 2022 Federal Circuit Newsletter (Chinese) Claims With Clerical Errors Can Be Judicially Corrected and Willfully Infringed In Pavo Solutions LLC v. Kingston…
May 2022 Federal Circuit Newsletter (Japanese) May 2022 Federal Circuit Newsletter (Chinese) Somebody’s Wrong: PTAB Must Resolve Conflicting Factual Testimony During IPR In Google LLC v. IPA Technologies Inc., Appeal…
April 2022 Federal Circuit Newsletter (Japanese) April 2022 Federal Circuit Newsletter (Chinese) A Construction That Eliminates the Entire Scope of Dependent Claims Should Be Avoided Littelfuse, Inc. v. Mersen USA…
March 2022 Federal Circuit Newsletter (Japanese) March 2022 Federal Circuit Newsletter (Chinese) Claim Limitation Not Disclosed by Any Reference but Disclosed by “Proposed Combination” of References Is Obvious In…
February 2022 Federal Circuit Newsletter (Japanese) February 2022 Federal Circuit Newsletter (Chinese) Ordered To Agree: Binding Settlement Agreement Provision Found Despite Absence of Singular, Executed Agreement In Plasmacam, Inc….
January 2022 Federal Circuit Newsletter (Japanese) January 2022 Federal Circuit Newsletter (Chinese) Silence May Support Negative Claim Limitation In Novartis Pharmaceuticals v. Accord Healthcare Inc. Appeal No. 21-1070, the…
December 2021 Federal Circuit Newsletter (Japanese) December 2021 Federal Circuit Newsletter (Chinese) Ranges for Interdependent and Interactive Components Can Be Tricky to Derive In Modernatx, Inc. v. Arbutus Biopharma…
November 2021 Federal Circuit Newsletter (Japanese) November 2021 Federal Circuit Newsletter (Chinese) Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer In Celgene Corp….
October 2021 Federal Circuit Newsletter (Japanese) October 2021 Federal Circuit Newsletter (Chinese) No Assembly, No Infringement – Federal Circuit Declines to Expand the “Final Assembler” Theory of Direct Infringement In…
September 2021 Federal circuit Newsletter (Japanese) September 2021 Federal Circuit Newsletter (Chinese) Arguments to the Patent Office That Contradict Information Submitted to the FDA Support an Inference of Deceptive…
